Zoetis: Strong Market Position and Growth Potential with New Product Launches and Strategic Initiatives

William Blair analyst Brandon Vazquez has maintained their bullish stance on ZTS stock, giving a Buy rating on May 21.

Brandon Vazquez has given his Buy rating due to a combination of factors that highlight Zoetis’s strong market position and growth potential. The company has a robust pipeline, particularly in the companion animal market, where it holds a first-mover advantage. Zoetis is actively working to increase the adoption of its product, Librela, through educational initiatives targeting both veterinarians and pet owners. This effort is expected to bolster its market presence and drive future growth.
Additionally, Zoetis is preparing to launch a new long-lasting osteoarthritis treatment, which is anticipated to gain approval soon. This product is expected to enhance compliance among pet owners and capture new market share. Despite competitive pressures, Zoetis has maintained its performance in key segments like dermatology and parasiticides, adhering to its pricing and strategic discipline. The company’s diagnostic business is also expanding in line with market trends, further supporting its growth outlook.

According to TipRanks, Vazquez is a 3-star analyst with an average return of 3.8% and a 50.00% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as PROCEPT BioRobotics, Neogen, and Align Tech.

In another report released on May 21, TD Cowen also maintained a Buy rating on the stock with a $202.00 price target.